2 research outputs found
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
<p>Abstract</p> <p>Background</p> <p>Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using inhibitors on the BRAF pathway as became an interesting therapeutic approach. In thyroid cancer cells the target molecules, implicated on the cellular effects, mediated by inhibition of BRAF are not well established. In order to fill this lack of knowledge we studied the proliferation and survival pathways and associated molecules induced by BRAF inhibition in thyroid carcinoma cell lines harbouring distinct genetic backgrounds.</p> <p>Methods</p> <p>Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib. Proliferation analysis was performed by BrdU incorporation and apoptosis was accessed by TUNEL assay. Levels of protein expression were analysed by western-blot.</p> <p>Results</p> <p>Both BRAF RNAi and sorafenib inhibited proliferation in all the cell lines independently of the genetic background, mostly in cells with BRAF<sup>V600E </sup>mutation. In BRAF<sup>V600E </sup>mutated cells inhibition of BRAF pathway lead to a decrease in ERK1/2 phosphorylation and cyclin D1 levels and an increase in p27<sup>Kip1</sup>. Specific inhibition of BRAF by RNAi in cells with BRAF<sup>V600E </sup>mutation had no effect on apoptosis. In the case of sorafenib treatment, cells harbouring BRAF<sup>V600E </sup>mutation showed increase levels of apoptosis due to a balance of the anti-apoptotic proteins Mcl-1 and Bcl-2.</p> <p>Conclusion</p> <p>Our results in thyroid cancer cells, namely those harbouring BRAF<sup>V600E</sup>mutation showed that BRAF signalling pathway provides important proliferation signals. We have shown that in thyroid cancer cells sorafenib induces apoptosis by affecting Mcl-1 and Bcl-2 in BRAF<sup>V600E </sup>mutated cells which was independent of BRAF. These results suggest that sorafenib may prove useful in the treatment of thyroid carcinomas, particularly those refractory to conventional treatment and harbouring BRAF mutations.</p
Syphilis and cirrhosis: a lethal combination in a XIX century individual identified from the Medical Schools Collection at the University of Coimbra (Portugal)
Syphilis is a chronic infection that is categorized by a three-stage progression. The tertiary stage may affect
bones and produce distinctive skull lesions called caries sicca. This paper aims to present an unusual case of syphilis
associated with a diagnosis of cirrhosis, which was recorded as the cause of death in a 28-year-old female in 1899.
The appearance and distribution of the lesions were compatible with acquired syphilis, as observed in the skull from
the Medical Schools Collection of the University of Coimbra. However, the cause of death was recorded as “hypertrophic
cirrhosis of the liver”, this is a condition that is compatible with several liver disorders, including a primary
liver disorder, such as cirrhosis provoked by alcoholism, infection of the liver by syphilis pathogens or by damage to
the liver from the use of mercury compounds, which was the common treatment for syphilis at the time. This paper
represents a contribution to the understanding of the natural evolution of syphilis